 		   Sonus Pharmaceuticals of Bothell, WA, has received a positive opinion on its EchoGen ultrasound contrast agent from the Committee of Proprietary Medicinal Products, the scientific review committee of the European Medicines Evaluation Agency (EMEA). Sonus expects the next regulatory step will be the issuance of a marketing authorization by the EMEA.	

Sonus Pharmaceuticals of Bothell, WA, has received a positive opinion on its EchoGen ultrasound contrast agent from the Committee of Proprietary Medicinal Products, the scientific review committee of the European Medicines Evaluation Agency (EMEA). Sonus

EchoGen moves closer to EU approval